Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.86 |
| ▸ | TSPO | P30536 | 1/20 | 0.86 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.77 |
| ▸ | BRD2 | P25440 | 4/20 | 0.73 |
| ▸ | BRD3 | Q15059 | 3/20 | 0.71 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.71 |
| ▸ | DNER | Q8NFT8 | 2/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | BRD1 | O95696 | 1/20 | 0.71 |
| ▸ | CCL2 | P13500 | 1/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.71 |
| ▸ | EP300 | Q09472 | 1/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17051091 | 0.93 | BRD4 (1.00) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL19465691 | 0.93 | BRD4 (1.00) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL12228301 | 0.93 | BRD4 (1.00) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL23317926 | 0.91 | BRD4 (0.83) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL21501429 | 0.90 | BRD4 (0.82) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL22054914 | 0.90 | BRD4 (0.82) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL22054919 | 0.90 | BRD4 (0.82) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL23657100 | 0.90 | BRD4 (0.82) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL24353326 | 0.90 | BRD4 (0.82) | BRD4ADORA3TSPOBRDTBRD2 | |
| SCHEMBL12228305 | 0.90 | BRD4 (0.82) | BRD4ADORA3TSPOBRDTBRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968620-B2 | Methods of treating lymphoma using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9968620-B2 | Methods of treating lymphoma using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9968619-B2 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9968619-B2 | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-15 | — | — | US | disclosed |
| US-9956228-B2 | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9956228-B2 | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9901583-B2 | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-02-27 | — | — | US | disclosed |
| US-9901583-B2 | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds | ONCOETHIX GMBH (CH) | 2018-02-27 | — | — | US | disclosed |
| US-9820992-B2 | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9820992-B2 | Method of treating non-small-cell lung cancer using pharmaceutical formulation containing thienotriazolodiazepine compounds | MERCK SHARP & DOHME CORP. (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2015168587-A1 | METHOD OF TREATING RESISTANT MULTIPLE MYELOMA AND MANTLE CELL LYMPHOMA USING THIENOTRIAZOLODIAZEPINE COMPOUNDS | ONCOETHIX SA (CH) | 2015-11-05 | — | — | WO | disclosed |
| US-9125915-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9125915-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20130261109-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-03 | — | — | US | disclosed |
| US-20130261109-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-10-03 | — | — | US | disclosed |
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476260-B2 | Antitumor agent | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100286127-A1 | ANTITUMOR AGENT | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-11 | — | — | US | disclosed |
| EP-2239264-A1 | ANTITUMOR AGENT | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261109-A1 | ANTITUMOR AGENT | BRPF3, BRDT, BRD4 | BRD4 3/4885ADORA3 3430/4885TSPO 3011/4885 |
| US-20100286127-A1 | ANTITUMOR AGENT | BRDT, HDAC1, BRPF3 | BRD4 4/4885ADORA3 3996/4885TSPO 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.